original ) (raw )Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Jin-Hyuk Choi
The Korean journal of internal medicine, 2017
View PDFchevron_right
Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)
Giannis Mountzios
Annals of Translational Medicine
View PDFchevron_right
Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders
Chi-li Chung
PLoS ONE, 2013
View PDFchevron_right
A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or ...
ELENI ISIDORA PERDIKOURI
Cancers, 2021
View PDFchevron_right
Management of EGFR mutated nonsmall cell lung carcinoma patients
Bogdan D. Grigoriu
The European respiratory journal, 2015
View PDFchevron_right
Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations
mingyang liu
Journal of thoracic disease, 2016
View PDFchevron_right
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations
Massimo Rugge
Oncotarget, 2017
View PDFchevron_right
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Luis Paz-ares
Journal of Cellular and Molecular Medicine, 2010
View PDFchevron_right
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms
Giuseppe Lo Russo
Tumori, 2017
View PDFchevron_right
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins
Jordi Remon , E. Dalmau
2014
View PDFchevron_right
EGFR Mutations Status For Non-Small-Cell Lung Cancer Patients
Alvydas Česas
Sveikatos mokslai
View PDFchevron_right
Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harbouring Rare Epidermal Growth Factor Receptor Mutations
Emmanuel De Laere , Elke Boone
Molecular Diagnosis & Therapy, 2015
View PDFchevron_right
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation
Junia C Costa
Lung Cancer
View PDFchevron_right
A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First or Second Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or M...
Giannis Mountzios
2021
View PDFchevron_right
How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations?
Hiroshige Yoshioka
Journal of Thoracic Oncology, 2013
View PDFchevron_right
Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis
Elena Dragioti
DOAJ (DOAJ: Directory of Open Access Journals), 2021
View PDFchevron_right
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Maria Arcila
Clinical Cancer Research, 2013
View PDFchevron_right
Uncommon EGFR mutations in lung adenocarcinomas: Clinical features and response to tyrosine kinase inhibitors
Emmanuel Watkin
Annals of Oncology, 2018
View PDFchevron_right
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Marta Guix
Clinical Cancer Research, 2011
View PDFchevron_right
Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer
S. Rampal
Lung Cancer, 2013
View PDFchevron_right
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao C
PLOS Medicine, 2005
View PDFchevron_right
Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
Emma Langley
Oncotarget, 2015
View PDFchevron_right
Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer
Edoardo Vattimo
Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2015
View PDFchevron_right
FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
Francesco Izzo
International Journal of Molecular Sciences
View PDFchevron_right
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
Toan Ho
Clinical and Translational Medicine
View PDFchevron_right
First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
Thomas Lynch
Journal of Clinical Oncology, 2008
View PDFchevron_right
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer
Laura Bonanno
Current Drug Targets, 2011
View PDFchevron_right
The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients
Terézia László
Pathology & Oncology Research, 2016
View PDFchevron_right
The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study
Ewelina Antoszewska , Janusz Limon
Journal of Cancer Research and Clinical Oncology, 2014
View PDFchevron_right
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Mauro Orlando
Cancer Research and Treatment, 2015
View PDFchevron_right
Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
Alexandra Voutsina
British journal of cancer, 2007
View PDFchevron_right
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
Anna Rachiglio
Cancers
View PDFchevron_right